"503A" and "503B" appear constantly in peptide marketing and are almost never explained. They are not quality tiers, they are not certifications, and neither one describes a product that FDA has reviewed. They are two sections of the same statute, describing two different permissions to make a drug that has not been approved.
This page sets out what each section requires, read from the statutory text and FDA's own published records, with the dates those records were read. It is journalism about a regulatory framework, not legal advice, and it cannot say where any particular product or seller sits.
The two permissions, in one sentence each
Section 503A — codified at 21 U.S.C. § 353a — covers a licensed pharmacist or licensed physician compounding a drug for an identified individual patient against a valid prescription order.
Section 503B — 21 U.S.C. § 353b — covers an outsourcing facility, defined in the statute as a facility at one geographic location that is engaged in compounding sterile drugs, has elected to register as an outsourcing facility, and complies with all of the section's requirements. The statute adds that an outsourcing facility "is not required to be a licensed pharmacy."
Both sections do the same basic work: they lift requirements that would otherwise make the drug unlawful to sell. What they lift is where they part company.
The difference that matters most is CGMP
Each section names the provisions of the Act it exempts a compounded drug from. Reading the two lists side by side is the fastest way to understand the whole framework.
| Requirement of the Act | Under 503A | Under 503B |
|---|---|---|
| § 355 — new drug approval | Exempt | Exempt |
| § 352(f)(1) — adequate directions for use | Exempt | Exempt |
| § 351(a)(2)(B) — current good manufacturing practice | Exempt | Not exempt |
That third row is the substance of the distinction. A 503B outsourcing facility must comply with CGMP: the manufacturing-quality regime that applies to drug manufacturers, covering process controls, testing, records and the rest. A 503A pharmacy compounding against a prescription is exempt from it, and is instead expected to work to the standards its state board and the applicable pharmacy compendia impose.
Neither exemption is a judgement about the resulting product. Both sections exist precisely because the product has not been through approval.
Whether a prescription is needed — and why that explains everything else
Under 503A, the exemptions are conditioned on compounding "based on the receipt of a valid prescription order or a notation, approved by the prescribing practitioner" that the compounded product is necessary for the identified patient. Limited quantities may be prepared ahead of a prescription only where there is a documented history of receiving valid orders for that product.
Under 503B, the statute says the opposite in plain words: an outsourcing facility "may or may not obtain prescriptions for identified individual patients."
That single clause is what the rest of 503B is built around. A facility making batches without a patient attached to each unit is doing something much closer to manufacturing, so the statute attaches the obligations of manufacturing: registration, fees, CGMP, adverse event reporting, and inspection.
What each facility owes, and what a stranger can check
503B registration is voluntary — a facility elects into it — and once inside, the obligations are specific and public in their effects:
- Registration, annually between 1 October and 31 December, with the facility's name, place of business, unique facility identifier and a point of contact email address.
- Fees under § 379j-62, which do not displace state pharmacy licensing fees.
- Inspection under section 374, on a risk-based schedule that the statute says accounts for compliance history, recall record, the inherent risk of the drugs compounded, the time since the last inspection, and whether the facility has declared an intent to compound from the shortage list.
- Adverse event reports submitted to FDA.
The practical consequence is a record. FDA publishes the registered outsourcing facilities as a table carrying, for each facility, its registration dates, its most recent inspection date, whether a Form 483 was issued, its recall history, and the actions taken after inspection. Read on 12 September 2026, the list carried roughly 120 facilities and was marked content current as of 8 September 2026. A facility that fails to re-register and pay by 31 December comes off the list on 1 January.
There is no counterpart for 503A. FDA's compounding questions and answers (content current as of 16 September 2025) states that "state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies" and that FDA "does conduct surveillance and for-cause inspections," against outsourcing facilities being "primarily overseen by FDA and inspected by FDA according to a risk-based schedule."
So the asymmetry a reader can actually use is not about quality. It is about who holds the record and whether it is published. For a 503B facility, the name can be looked up and the inspection history read. For a 503A pharmacy, the oversight sits with a state board and produces no national public file.
Neither of those facts makes a compounded drug an approved one. FDA's own sentence is the one to keep: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
The part that decides which peptides are involved: two separate ingredient lists
Each section restricts what a compounder may start from, and the two rules are not the same rule.
Under 503A, a bulk drug substance qualifies if it complies with an applicable United States Pharmacopoeia or National Formulary monograph; or, where no monograph exists, is a component of a drug approved by the Secretary; or appears on a list developed by the Secretary through regulation. It must also come from a registered establishment and be accompanied by a valid certificate of analysis.
Under 503B, the door is narrower in the way that matters: the substance must appear on FDA's list of bulk drug substances for which there is a clinical need, established through a Federal Register process, or the drug compounded from it must be on the drug shortage list at the time it is compounded and distributed. A monograph alone is not enough. The substance must still come from a registered establishment with a valid certificate of analysis — the same kind of document our guide to reading a certificate of analysis covers.
That is worth stating plainly, because it inverts the intuition the numbers create: the more heavily regulated facility type has the narrower ingredient door. 503A offers three routes, two of which require no FDA decision about that particular substance. 503B requires an affirmative FDA listing or an active shortage.
Most research peptides have no USP or NF monograph and are not components of approved drugs, which means the first two 503A routes are closed to them as well, and a place on the 503A list is what would be needed. That first door is also the one invoked, usually without noticing, by any product page describing its contents as USP grade — a claim that asserts the existence of exactly the monograph these compounds lack.
The same peptide, two different answers
FDA also maintains a table of bulk drug substances that may present significant safety risks — "category 2" — and here the two-list architecture becomes visible. As the page stood on 22 April 2026:
| Substance | Listed under | Date |
|---|---|---|
| GHRP-2 | 503B only | 29 September 2023 |
| GHRP-6 | 503B only | 29 September 2023 |
| Ipamorelin acetate | 503B only | 29 September 2023 |
| Kisspeptin-10 | 503A only | 29 September 2023 |
| Ibutamoren mesylate | 503A and 503B | 29 September 2023 (503A); 29 December 2022 (503B) |
Four of the five peptide-class entries are listed under exactly one section. Only ibutamoren appears under both — and on dates nine months apart, the 503B entry arriving first.
The reason is procedural rather than pharmacological. The two lists are compiled from nominations, made under one section or the other, evaluated separately and acted on separately. A substance that nobody nominated under a section does not appear on that section's list, whatever FDA may have concluded about it elsewhere.
Which produces the rule worth carrying away from this page: absence from one list is not a clearance under that section. The question "has FDA restricted ipamorelin?" has two correct and opposite answers depending on which kind of compounder is being asked about, and a page that gives only one of them is not wrong so much as incomplete.
The same page carries a separate section for substances "nominated but withdrawn," where several of the most-searched research peptides sit — BPC-157, CJC-1295, AOD-9604 among them. Their position, and the common misreporting of it in both directions, is covered on our page on what the rules actually say about peptides. We also publish the whole table as an index — all fourteen substances with their sections and dates, and all sixteen withdrawn nominations — because the section column is the part most often dropped when it is quoted second-hand.
What this does not tell anyone
These two numbers describe permissions granted to compounders. They say nothing about a vial bought from a research supplier, which sits in a different part of the framework entirely — the caution-labelled shipping route of 21 CFR 312.160, and the intended-use reasoning FDA applies to it in the warning letters we track.
They also say nothing about a finished product's contents. A facility's registration status is a fact about the facility. What is in a particular vial is a question answered by testing it, which is why this publication's testing methodology treats an identity and purity result as the claim and a registration number as context.
Where a specific product, seller or transaction sits under either section is a legal question, and one for a lawyer rather than a publisher.
Sources read for this page
- 21 U.S.C. § 353a — FD&C Act section 503A, pharmacy compounding. Read 12 September 2026.
- 21 U.S.C. § 353b — FD&C Act section 503B, outsourcing facilities. Read 12 September 2026.
- FDA, Registered Outsourcing Facilities. Content current as of 8 September 2026; read 12 September 2026.
- FDA, Compounding and the FDA: Questions and Answers. Content current as of 16 September 2025; read 12 September 2026.
- FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of 22 April 2026; read 12 September 2026.